CTMX · CytomX Therapeutics, Inc.

Revenue fell sharply 79.9% year-over-year to $10.3 million in Q1 FY2026 from $50.9 million, primarily because performance obligations under the BMS and Amgen collaborations were completed in the prior period. This normalization of collaboration revenue, which had driven elevated recognition in Q1 FY2025, directly impacted profitability metrics. Operating income deteriorated to a $19.7 million loss from a $22.6 million profit, yielding an operating margin of -191.8%, as the revenue base shrank while research and development expenses continued to support the clinical pipeline.

Net income followed suit, posting an $18.2 million loss versus $23.5 million profit a year ago, underscoring the transition from milestone-heavy revenue to a more predictable but lower run-rate model. Operating cash flow reflected heightened use of $25.5 million, worsening from $21.0 million, due to working capital outflows including the drop in deferred revenue tied to completed collaborations. With no capital expenditures, free cash flow matched operating cash use at -$25.5 million, signaling disciplined capital allocation toward clinical advancement rather than infrastructure.

Management commentary emphasizes focus on Varseta-M program development, with expected continued growth in related spend as future quarters prioritize this asset alongside other clinical efforts. The company affirms that, based on its current operating plan and liquidity requirements, existing capital resources will suffice to fund operations into at least the second half of 2028. This provides over two years of runway visibility, assuming no material deviations from anticipated results. Should operating outcomes fall short, planned expenditures may require reduction to extend the funding period. Positive clinical signals, such as Phase 1 expansion efficacy data, support pipeline progression, though key risks remain around trial outcomes and execution in monotherapy and combination settings.